Madopar - Benserazide

Mabertin - Temazepam Mablin - Busulfan Macasirool - Furosemide Macmiror - Nifuratel Macocyn - Dxytetracycline Macphenicol -Thiamphenicol Macrodantin - Nitrofurantoin Macro-Dil - Midecamycin Madaprox - Naproxen Madar - Nordazepam Madecitina - Metampicillin sodium Madelen - Drnidazole Madlexin - Cephalexin Madopar - Benserazide Madopark - Benserazide... 

Sinemet (Merck Sharp Dohme)-comb. with carbidopa Larodopa (Roche) Madopar (Roche)-comb. with benserazide Sinemet (Du Pont)-comb. with carbidopa Doparl (Kyowa)... 

Monolithic non-gas-generating systems are matrix tablets consisting of hydrocolloids that form an external gel layer when hydrated. The internal tablet core remains dry with an overall density lower than that of the gastric fluid. Hydroxypropylmethycellulose (HPMC) is the most commonly used hydrocolloid. This approach has been developed into marketed drug products as the Hydrodynamically Balanced System (HBS) invented by Sheth and Tossounian.93 Gastric retention and flotation times up to 6 hours were achieved. Valrelease (diazepam) and Madopar (levodopa and benserazide) were two marketed products developed using this approach. 

Benserazide Madopar (with L-dopa) Madopar (with L-dopa)... 

Madopar (Roche)-comb. with benserazide Sinemet (Du Pont)-comb. with carbidopa... 

Minimisation of unwanted effects. Combining levodopa with benserazide (Madopar) or with carbidopa (Sinemet) slows its metabolism outside the central nervous system so that smaller amounts of levodopa can be used this reduces adverse effects. 

HBS Hydrodynamically balanced system. A CR oral dosage form (capsule or tablet), which is designed to prolong the residence time within the stomach. Increased time for dissolution, prolonged absorption phase, and improved pharmacokinetic profile. Madopar HBS or Prolopa HBS (L-dopa + Benserazide) Vahelease (diazepam). 

He WW, Zhou XW, Lu JQ. Capillary electrophoresis-chemiluminescence detection of levodopa and benserazide in Madopar tablet. Chin Chem Lett 2007 18 91-3. 

Wang C, Huang P, Liu Y. Simultaneous determination of levodopa and benserazide in madopar tablets by HPLC-ECD. Zhongguo Yiyuan Yaoxue Zazhi 2003 23 517-9. 

Ceballos-Baumann, A.O., Von Kummer, R., Eckert, W. and Weicker, H. (1990) Controlled-release L-dopa/benserazide (Madopar HBS) clinical observations and L-dopa and dopamine plasma concentrations in fluctuating parkinsonian patients. J. Neurol. 237 24-28. 

In a study using Madopar HBS, a sustained-release preparation of levodopa and benserazide, the concurrent use of an unnamed antacid reduced the levodopa bioavailability by about one-third in healthy subjects. The manufacturers of Madopar CR state that antacids reduce the bioavailability of levodopa from the controlled-release preparation in comparison with conventional Madopar. ... 

Madopar CR (Levodopa/benserazide l drochloride). Roche Products Ltd. UK Summary of product characteristics, January 2006. 

The interaction between the non-selective MAOIs (listed in Table 32.1 , (p. 1130)) and levodopa on its own is well documented, serious and potentially life-threatening. Patients should not be given levodopa on its own during treatment with any of these MAOIs, nor for a period of 2 to 3 weeks after their withdrawal. Note that this interaction is inhibited by the presence of dopa-decarboxylase inhibitors such as carbidopa and benserazide (as in Sinemet and Madopar) so that a serious interaction is unlikely to occur with these preparations. Even so, the manufacturers continue to list the MAOIs among their contraindications. 

---